Prognostic role of the initial portal pressure gradient reduction after TIPS in patients with cirrhosis

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 10, 2007, Pages 846-852

  Biecker, Erwin ^a   Roth, Felix ^a   Heller, Jörg ^a   Schild, Hans H ^a   Sauerbruch, Tilman ^a   Schepke, Michael ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Cirrhosis; Oesophageal varices; Portal hypertension; Prognosis; Rebleeding; Transjugular intrahepatic portosystemic stent shunt

Indexed keywords

BILIRUBIN; CREATININE; SODIUM;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; ASCITES; BLOOD LEVEL; CHOLESTATIC HEPATITIS; CONTROLLED STUDY; DISEASE SEVERITY; ESOPHAGUS VARICES BLEEDING; FEMALE; FOLLOW UP; HEMODYNAMIC PARAMETERS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRESSURE GRADIENT; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SURGICAL TECHNIQUE; SURVIVAL RATE; VIRUS HEPATITIS;

AGED; EPIDEMIOLOGIC METHODS; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PORTAL PRESSURE; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; POSTOPERATIVE PERIOD; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 34548699110     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282eeb488     Document Type: Article

References (38)

1. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80:800-809.
2. De la Pena J, Brullet E, Sanchez-Hernandez E, Rivero M, Vergara M, Martin-Lorente JL, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005; 41:572-578.
3. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005; 41:386-400.
4. Papatheodoridis GV, Goulis J, Leandro G, Patch D, Burroughs AK. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. Hepatology 1999; 30:612-622.
5. Henderson JM, Boyer TD, Kutner MH, Galloway JR, Rikkers LF, Jeffers LJ, et al. Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial. Gastroenterology 2006; 130:1643-1651.
6. Burroughs AK, Vangeli M. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis. Scand J Gastroenterol 2002; 37:249-252.
7. Wong F. The use of TIPS in chronic liver disease. Ann Hepatol 2006; 5:5-15.
8. De Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43:167-176.
9. Gulberg V, Schepke M, Geigenberger G, Holl J, Brensing KA, Waggershauser T, et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scand J Gastroenterol 2002; 37:338-343.
10. Merkel C, Bolognesi M, Bellon S, Zuin R, Noventa F, Finucci G, et al. Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology 1992; 102:973-979.
11. Villanueva C, Minana J, Ortiz J, Gallego A, Soriano G, Torras X, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345:647-655.
12. Vorobioff J, Groszmann RJ, Picabea E, Gamen M, Villavicencio R, Bordato J, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996; 111:701-709.
13. Vinel JP, Cassigneul J, Levade M, Voigt JJ, Pascal JP. Assessment of short-term prognosis after variceal bleeding in patients with alcoholic cirrhosis by early measurement of portohepatic gradient. Hepatology 1986; 6:116-117.
14. Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C, Jimenez E, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40:793-801.
15. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47:288-295.
16. Patch D, Nikolopoulou V, McCormick A, Dick R, Armonis A, Wannamethee G, et al. Factors related to early mortality after transjugular intrahepatic portosystemic shunt for failed endoscopic therapy in acute variceal bleeding. J Hepatol 1998; 28:454-460.
17. Polio J, Groszmann RJ. Hemodynamic factors involved in the development and rupture of esophageal varices: a pathophysiologic approach to treatment. Semin Liver Dis 1986; 6:318-331.
18. Casado M, Bosch J, Garcia-Pagan JC, Bru C, Banares R, Bandi JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998; 114:1296-1303.
19. Garcia-Tsao G, Groszmann R, Fisher R, Conn H, Atterbury C, Glickmann M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985; 5:419-424.
20. Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99:1401-1407.
21. Cabrera J, Maynar M, Granados R, Gorriz E, Reyes R, Pulido-Duque JM, et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology 1996; 110:832-839.
22. Jalan R, Forrest EH, Stanley AJ, Redhead DN, Forbes J, Dillon JF, et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology 1997; 26:1115-1122.
23. Sauer P, Theilmann L, Stremmel W, Benz C, Richter GM, Stiehl A. Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology 1997; 113:1623-1631.
24. Siegerstetter V, Rössle M. The role of TIPS for the treatment of portal hypertension: effects and efficacy. Acta Gastroenterol Belg 1997; 60:233-237.
25. Somberg KA, Riegler JL, LaBerge JM, Doherty-Simor MM, Bachetti P, Roberts JP, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am J Gastroenterol 1995; 90:549-555.
26. Rössle M, Siegerstetter V, Olschewski M, Ochs A, Berger E, Haag K. How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts. Am J Gastroenterol 2001; 96:3379-3383.
27. Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346:1056-1059.
28. Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334:1624-1629.
29. McCormick PA, Patch D, Greenslade L, Chin J, McIntyre N, Burroughs AK. Clinical vs haemodynamic response to drugs in portal hypertension. J Hepatol 1998; 28:1015-1019.
30. Valla D, Jiron MI, Poynard T, Braillon A, Lebrec D. Failure of haemodynamic measurements to predict recurrent gastrointestinal bleeding in cirrhotic patients receiving propranolol. J Hepatol 1987; 5:144-148.
31. Moitinho E, Escorsell A, Bandi JC, Salmeron JM, Garcia-Pagan JC, Rodes J, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999; 117:626-631.
32. Patch D, Armonis A, Sabin C, Christopoulou K, Greenslade L, McCormick A, et al. Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding. Gut 1999; 44:264-269.
33. Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 32:930-934.
34. Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, et al. Improved clinical outcome using polytetrafluoroethylene- coated stents for TIPS: results of a randomized study. Gastroenterology 2004; 126:469-475.
35. Ockenga J, Kroencke TJ, Schuetz T, Plauth M, Kasim E, Petersein J, et al. Covered transjugular intrahepatic portosystemic stents maintain lower portal pressure and require fewer reinterventions than uncovered stents. Scand J Gastroenterol 2004; 39:994-999.
36. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464-470.
37. Llach J, Gines P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94:482-487.
38. Schepke M, Roth F, Koch L, Heller J, Rabe C, Brensing KA, et al. Prognostic impact of renal impairment and sodium imbalance in patients undergoing transjugular intrahepatic portosystemic shunting for the prevention of variceal rebleeding. Digestion 2003; 67:146-153.